Insulet (PODD) Cash & Equivalents (2010 - 2026)

Insulet has reported Cash & Equivalents for 17 years, with the latest figure at $480.4 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents fell 62.56% year-over-year to $480.4 million; the trailing twelve-month figure through Mar 2026 stood at $480.4 million (down 62.56% YoY), and the FY2025 full-year result was $716.1 million, down 24.89% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $480.4 million, down from $716.1 million in the prior quarter.
• The five-year high for Cash & Equivalents was $1.3 billion in Q1 2025, with the low at $480.4 million in Q1 2026.
• Historically, Cash & Equivalents has averaged $780.7 million across 5 years, with a median of $716.1 million in 2025.
• Annual changes were most pronounced in 2025 — Cash & Equivalents surged 70.81% — and 2026, when it sank 62.56%.
• Insulet's Cash & Equivalents stood at $674.7 million in 2022, then rose by 4.37% to $704.2 million in 2023, then jumped by 35.39% to $953.4 million in 2024, then slipped by 24.89% to $716.1 million in 2025, then tumbled by 32.91% to $480.4 million in 2026.
• The last three Cash & Equivalents figures came in at $480.4 million (Q1 2026), $716.1 million (Q4 2025), and $757.4 million (Q3 2025), per Business Quant data.